Aim: To present the technique and efficiency of intravitreal recombinant tissue plasminogen activator (r-TPA) and gas injection in acute submacular hemorrhage (SMH) due to traumatic choroidal rupture. Patients and Methods: 0.4 ml of sulfur hexafluoride was injected into the vitreous cavity in 2 patients with SMH due to traumatic choroidal rupture. In 1 patient gas injection was combined with 50 µg r-TPA. Both patients were closely followed. Results: Preoperative visual acuity was 20/125 in one eye and 20/100 in the other. At the end of the follow-up, visual acuity had improved to 20/32 in both eyes. Conclusion: r-TPA and gas injection into the vitreous body may be an efficient therapy in patients with submacular hemorrhage due to choroidal rupture.

Keywords:
Choroidal rupture, Intravitreal gas, Submacular hemorrhage, Recombinant tissue plasminogen activator, Ocular trauma
1.
Glatt H, Machemer R: Experimental subretinal hemorrhage in rabbits. Am J Ophthalmol 1982;94:762–773.
2.
Kamei M, Tano Y, Maeno T, Ikuno Y, Mitsunda H, Yuasa T: Surgical removal of submacular hemorrhage using tissue plasminogen activator and perfluorcarbon liquid. Am J Ophthalmol 1996;121:267–275.
3.
Ibanez HE, Williams DF, Thomas MA, Ruby AJ, Meredith TA, Boniuk I, Grand MG: Surgical management of submacular hemorrhage: A series of 47 consecutive cases. Arch Ophthalmol 1995;113:62–69.
4.
Herriot W: Intravitreal gas and TPA: An outpatient procedure for subretinal hemorrhage. Vail Vitrectomy Meet, Vail, March 1996.
5.
Ohji M, Saito Y, Hayashi A, Lewis JM, Tano Y: Pneumatic displacement of subretinal hemorrhage without tissue plasminogen activator. Arch Ophthalmol 1998;116:1326–1332.
6.
Wyszynski RE, Grossniklaus HE, Frank KE: Indirect choroidal rupture secondary to blunt ocular trauma. Retina 1988;8:237–234.
7.
Benson WE, Jeffers JB: Blunt trauma; in Benson WE (ed): Duane’s Clinical Ophthalmology. Philadelphia, Lippincott, 1997, vol 3, 31, pp 10–12.
8.
Framme C, Toukhy HE, Sachs HG, Spiegel D, Roider J, Gabel VP, Lohmann CP: Clinical results of intravitreal administration of tissue-type plasminogen activator (tPA) and gas for removal of subretinal hemorrhage in senile macular degeneration. Klin Monatsbl Augenheilkd 2000;216:33–39.
9.
Hesse L, Schmidt J, Kroll P: Management of acute submacular hemorrhage using recombinant tissue plasminogen activator and gas. Graefes Arch Clin Exp Ophthalmol 1999;237:273–277.
10.
Dureau P, Legat L, Neuner-Jehle M, Bonnel S, Pecqueur S, Abitbol M, Dufier JL: Quantitative analysis of subretinal injections in the rat. Graefes Arch Clin Exp Ophthalmol 2000;238:608–614.
11.
Bennett SR, Folk JC, Blodi CF, Klugman M: Factors prognostic of visual outcome in patients with subretinal hemorrhage. Am J Ophthalmol 1990;109:33–37.
12.
Hassan AS, Johnson MW, Schneiderman TE, Regillo CD, Tornambe PE, Poliner LS, Blodi BA, Elner SG: Management of submacular hemorrhage with intravitreous tissue plasminogen activator injection and pneumatic displacement. Ophthalmology 1999;106:1900–1907.
13.
Irvine WE, Johnson MW, Hernandez E, Olsen KR: Retinal toxicity of human tissue plasminogen activator in vitrectomized rabbit eyes. Arch Ophthalmol 1991;109:718–722.
14.
Williamson J, Forrester JV: Treatment of vitreous haemorrhage with urokinase. Lancet 1973;i:888.
15.
Schmitz K, Kreutzer B, Hitzer S, Behrens-Bauman W: Therapy of subhyaloidal hemorrhage by intravitreal application of rtPA and SF(6) gas. Br J Ophthalmol 2000;84:1324–1325.
16.
Forrester JV, Edgar W, Prentice CRM, Forbes CD, Williamson J: The effect of fibrinolytic inhibition in the resolution of experimental vitreous hemorrhage. Am J Ophthalmol 1977;84:810–814.
17.
Min WK, Kim YB, Lee KM: Treatment of experimental vitreous hemorrhage with tissue plasminogen activator. Korean J Ophthalmol 1990;4:12–15.
18.
Kokame GT: Vitreous hemorrhage after intravitreal tissue plasminogen activator (t-PA) and pneumatic displacement of submacular hemorrhage. Am J Ophthalmol 2000;129:546–547.
© 2004 S. Karger AG, Basel
2003
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.